The power of meta-analysis in therapeutic decision making for advanced kidney cancer

Ulka Vaishampayan


Despite being a relatively uncommon cancer, kidney cancer has made tremendous advances over the past two decades. In fact, it has served as the blueprint for proof of principle of various targeted and immune therapies. A plethora of clinical trials have been reported and completed in this disease within the last decade.